Biotech News

Context Therapeutics Reports Third Quarter 2026 Financial Results and Pipeline Progress

Context Therapeutics (CNTX)Context TherapeuticsEarnings

CTIM-76 weekly dosing at 140–280 µg in heavily pretreated PROC: 22% confirmed ORR, 56% confirmed DCR, and median PFS of 5.6 months Dose escalation to 420 µg every three weeks is ongoing following completion of the DLT assessment period at 280 µg Phase 1b initiation expected in Q1 2027 and initial

Related news

Context Therapeutics

Solid-Tumor T-Cell Engagers Context Therapeutics develops bispecific antibodies that bind a tumor antigen and CD3 to recruit T cells against solid tumors. CTIM-76 CTIM-76 targets Claudin 6 and CD3. It is the company's lead Phase 1 program in tumors expressing the developmentally restricted CLDN6 antigen. CT-95 CT-95 is a...

Recent company news

Stock data

Close
0.17 USD
Market cap
222.35M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States